Nexgenia and Seattle Children’s Research Institute Join Forces to Advance Immunotherapy Research Efforts Developing novel reagents designed to improve the efficiency and effectiveness of cancer immunotherapies Seattle, WA – October 19 – Nexgenia, a privately held biotechnology company focused on the development and manufacture of proprietary polymer-based reagents, is..
Read more
Cancer immunotherapy was highlighted in the Seattle Business Magazine’s December issue. Nexgenia was featured as a company with tools to help the manufacturing process of cell-based cancer immunotherapies. Read the full article here.
Nexgenia was featured in the online news of the Puget Sound Business Journal. Read the article here.
Nexgenia’s new CEO shifts focus to cell separations and immunotherapy product development. Read the press release from the UW C4C below. Nexgenia News Release
On August 29, The Life Sciences Discovery Fund (LSDF) announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. Nexgenia’s project to develop and validate technology for increasing the speed and..
Read more
In June 2014, Drs. Thomas Schulte and Barrett Nehilla traveled to Dresden, Germany to present recent results on the synthesis of stimuli-responsive magnetic nanoparticles at the 10th International Conference on the Scientific and Clinical Applications of Magnetic Carriers. They also presented at the TechConnect World Innovation Conference and Expo in..
Read more